| Eligibility |
Inclusion Criteria:
- Subject is a non-smoking male or female adult
- Subject (females) must be of non-childbearing potential or if of childbearing
potential, subject must not be pregnant or breastfeeding, and must agree to use highly
effective birth control and must not donate ova through 30 days after last dose of
study drug.
- Subject (males) must agree to use contraception to prevent pregnancy/partner exposure
and must not donate sperm through 30 days after last dose of study drug.
- Subject has a body mass index (BMI) 19 to 30 kg/m^2, inclusive and weighs at least 50
kg
- Subject is healthy as determined by the Principal Investigator or designee based on
medical history and physical examinations performed at Screening and Day -1 of Period
1
- Subject must be willing and able to comply with the study diet, willing to abstain
from strenuous physical activity which could cause muscle aches or injury, including
contact sports for a period of 48 hours prior to study and through follow-up visit.
- Subject must be willing and able to give and understand written informed consent,
communicate well with the PI, and comply with the study procedures, requirements and
restrictions
- Part B: subject was born in China, with 2 Chinese biological parents and 4 Chinese
grandparents as confirmed by interview, has lived no longer than 10 years outside of
China, and has had no significant change in lifestyle, including diet, since leaving
China
Exclusion Criteria:
- Subject is planning to conceive a child during the study or within 1 month after the
last dose of TD 1473
- Subject has evidence or history of clinically significant allergic disease,
hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
psychiatric, or neurological disease
- Subject has history of venous thrombosis
- Subject has any clinically significant abnormalities in the results of laboratory
evaluations, or liver function tests exceeding the upper limit of normal in the
screening or pre-dose period
- Subject has creatinine clearance as calculated by Cockcroft-Gault formula <90mL/min at
screening or pre-dose period.
- Subject has any medical condition possibly affecting drug absorption
- Subject has history of lymphoma, leukemia, or other types of malignancy
- Subject previously participated in a study for TD 1473 and/or subject has previously
taken tofacitinib or other JAK inhibitors.
- Subject participated in another clinical trial of an investigational drug (or medical
device) within 30 days
- Subject is unwilling to abstain from ingestion of caffeine or xanthine-containing
products
- Subject is unwilling to abstain from alcohol beginning 24 hours prior to study start
- Subject has history of alcoholism or drug abuse
- Female subject who is pregnant and/or lactating
- Subject has positive results at Screening for human immunodeficiency virus (HIV),
hepatitis A virus (HAV) antibodies, hepatitis B virus antigen (HBsAg), hepatitis B
core antibodies (HBcAb), or hepatitis C virus (HCV) antibody
- Subject has confirmed or suspected severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection (COVID-19)
- Subject consumed grapefruit/Seville orange and/or grapefruit juice within 14 days
prior to study
- Subject consumed cruciferous vegetables (e.g., kale, broccoli, watercress, collard
greens, kohlrabi, Brussels sprouts, mustard greens) or charbroiled meats beginning 7
days prior to study start and is unwilling to abstain from consuming such vegetables
during the study
- Subject uses or has used nicotine-containing products within 6 months prior to study
start
- Subject has acute illness (GI illness, infection (e.g., influenza) or know
inflammatory process) at screening or pre-dose period.
- Subject has poor venous access that limits phlebotomy
- Subject donated blood or had significant blood loss within 56 days prior to study
start
- Subject donated plasma within 7 days prior to study start
- Subject has abnormal screening ECG based on certain parameters or designated by the PI
or designee to be clinically significant.
- Subject has personal or known family history of congenital long QT syndrome or known
family history of sudden death
- Subject has history of hypersensitivity to drugs with a clinically significant
reaction or any clinically significant hypersensitivities
- Subject has known hypersensitivity to contents of the study drug including excipients,
or drugs from a similar chemical class as TD-1473
- Subject has history of severe allergic reaction or severe hypersensitivity or
idiosyncratic reaction to any food, medication, insect or bee sting, or previous
status asthmaticus (e.g., acute severe asthma attacks)
- Subject has history of latent or active tuberculosis
- Subject received a live viral vaccine within 8 weeks of study start
- Subject, who, for any reason, is deemed by the Principal Investigator, designee, or
Sponsor to be inappropriate for this study or have any condition which would confound
or interfere with the evaluation of the safety, tolerability, and PK of the
investigational drug or prevent compliance with the study protocol
|
